Research · November 9, 2026

StimCardio's $30M Series A — A Wearable That Treats the Heart Between Procedures

StimCardio raised $30 million in an oversubscribed Series A led by Metis Medtech to fund a pivotal trial of Rhyvive, a wrist-worn wearable that delivers non-invasive median nerve stimulation at home to reduce atrial fibrillation recurrence after catheter ablation — backed by a sham-controlled pilot published in Heart Rhythm.

What happened

On October 29, 2026, StimCardio Medical, a Los Angeles-based clinical-stage medical device company, announced the closing of an oversubscribed $30 million Series A financing. The round was led by Metis Medtech, the family office of John Slump, with participation from Catalyst Health Ventures, multiple corporate strategic investors, and other new and existing investors. The company says the financing is expected to fund it through its planned NeuroPulse 2 pivotal study and the preparation of a De Novo submission to the U.S. Food and Drug Administration (FDA).

The framing is a gap claim, not a device claim. Catheter ablation is an established, guideline-recommended treatment for atrial fibrillation (AF), but the procedure is not the end of the story: the announcement cites a recurrence rate of approximately 30% to 40% after an initial ablation. StimCardio's argument is that treatment currently stops at the procedure room door, and that the months after ablation — when recurrence actually happens — are therapeutically empty. Its answer is a wearable that keeps treating the patient at home.

What Rhyvive actually does

Rhyvive, StimCardio's lead investigational product, is a wrist-worn therapeutic wearable designed to deliver personalized, non-invasive median nerve stimulation (MNS) through a closed-loop system that integrates physiological sensing and neuromodulation. Developed as an adjunct to catheter ablation rather than a replacement for it, it is designed to modulate autonomic nervous system pathways with the goal of reducing recurrent atrial arrhythmias such as AF.

Two parts of that description do real work. “Closed-loop” means the device is not a fixed stimulator on a timer: it senses physiology and adjusts stimulation, which is the difference between a gadget that buzzes on schedule and a therapy that responds to the patient's state. And “adjunct” is a positioning choice with regulatory consequences: Rhyvive is not competing with ablation, the established standard, but attaching itself to the ablation patient's journey — a much narrower, more defensible claim than a standalone AF cure, and the reason the pivotal trial is designed as wearable-plus-ablation versus ablation alone.

The context numbers the company cites are large and sourced, not invented: approximately 59 million people worldwide living with AF, per a 2025 analysis of Global Burden of Disease data published in the Journal of the American College of Cardiology, and ablation recommended as first-line rhythm control therapy for selected patients under the 2023 ACC/AHA/ACCP/HRS clinical guidelines. Even with advances including pulsed field ablation (PFA), the company notes, recurrence remains a persistent clinical challenge — which is precisely the gap Rhyvive is built to fill.

Why the pilot matters more than the round

The financing follows the presentation of StimCardio's NeuroPulse 1 pilot study as a late-breaking clinical trial at HRX Live 2026 and its peer-reviewed publication in Heart Rhythm. The study was randomized, double-blind, and sham-controlled — the design that matters for a neuromodulation device, where placebo effects are a genuine confound — and it demonstrated a statistically significant reduction in recurrent atrial arrhythmia events post-ablation with active MNS stimulation compared with the sham group.

That design is what separates this round from a typical device funding story. A sham-controlled pilot with peer-reviewed publication is evidence, not just a prototype: it means the company has already survived the hardest early test for a stimulation therapy, which is proving the effect is in the stimulation and not in the wearing. NeuroPulse 2, the multicenter pivotal trial this round funds, is the step that converts that pilot signal into a regulatory submission — a De Novo pathway, which is the FDA route for novel devices with no predicate, and a harder bar than a 510(k) clearance built on an existing device.

The investor mix is also doing specific work. Metis MedTech is led by John Slump, who sits on StimCardio's board and whose track record the announcement cites as four major medical device exits, including two in the cardiac electrophysiology market — Farapulse and Atraverse Medical — representing more than $1.25 billion in aggregate M&A transaction value. Catalyst Health Ventures' managing partner Joshua Phillips, also a board member, frames the bet as “paradigm-shifting technologies with the potential to transform patient care.” In other words, the round is led by operators who have sold into exactly this market before, not by generalist capital discovering cardiology.

CEO Amir Soltanianzadeh frames the ambition in category terms: “Our vision is to establish non-invasive neuromodulation as a new therapeutic category in cardiac electrophysiology.” That is a bigger claim than one device — a category, not a product — and the longer-term vision in the announcement extends wearable neuromodulation into additional AF and cardiovascular applications beyond post-ablation care.

Why this is a different bet from the other clinical stories

This queue has recently featured clinical-stage companies, but StimCardio is a different kind of clinical bet. KymaThera is a drug: a small molecule that must survive the long, attritional path of dose escalation, safety, and efficacy readouts before it ever reaches a patient. Vera Health is software: an evidence-grading search layer that helps clinicians decide, without itself treating anyone. StimCardio is a therapeutic device with a closed-loop mechanism and a sham-controlled pilot already published — it treats, but it treats between procedures, in the patient's home, as an adjunct rather than a replacement.

That distinction sets both the opportunity and the risk. A device that works at home, non-invasively, after a procedure patients already undergo has a distribution path that a new drug does not: every ablation patient is a potential candidate, and the therapy does not ask the cardiologist to abandon the procedure they trust. But the risk is equally specific. Neuromodulation effects can be modest, variable across patients, and hard to sustain outside trial conditions; a pivotal trial that compares wearable-plus-ablation against ablation alone must show a benefit large enough to justify a device patients wear daily, and the De Novo pathway means the FDA will scrutinize a novel mechanism without a predicate to lean on.

What this does not show

The announcement discloses no valuation, revenue, or pricing figure, and no patient count, effect size, or follow-up duration for the NeuroPulse 1 pilot — only that the reduction was statistically significant. It gives no enrollment target, site count, or readout date for NeuroPulse 2, and no timeline for the De Novo submission beyond preparation. The 30–40% recurrence figure and the 59-million-patient figure are cited context, not StimCardio's own results, and the “first-of-its-kind” description of the pivotal study is the company's framing, not an independent assessment. Rhyvive remains investigational, as the announcement's own caution states: limited by United States law to investigational use.

What would turn this round from a promising pilot into a category is the NeuroPulse 2 readout itself: a multicenter, pivotal demonstration that adding wearable neuromodulation to ablation improves outcomes versus ablation alone, at a magnitude that justifies daily wear, on a timeline that supports a De Novo submission. Until then, StimCardio has the more defensible half of the device pitch — a real gap after ablation, and a sham-controlled signal that stimulation, not suggestion, closes some of it — and the harder half still to prove: that the signal survives scale, time, and the home.

---

Sources